{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:41:47Z","timestamp":1792788107483,"version":"4.5.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":89,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Zhejiang University\u2013Jinsai Joint Fund","award":["ZJU-GENSCI2024ZD003"],"award-info":[{"award-number":["ZJU-GENSCI2024ZD003"]}],"id":[{"id":"https:\/\/ror.org\/00a2xv884","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>McCune\u2013Albright Syndrome (MAS) is a rare, mosaic genetic disorder characterized by fibrous dysplasia of bone, endocrine hyperfunction, and skin pigmentation. Despite increasing clinical recognition, real-world data on diagnostic timelines, disease burden, and psychosocial impact among MAS patients\u2014particularly in China\u2014remain scarce.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a national, cross-sectional survey of Chinese MAS patients between November 2024 to June 2025 using a structured 95-item online questionnaire disseminated via the McCune\u2013Albright Syndrome Clinical Research Consortium (MASCRC) database and the Bone Care Center patient community. Responses were de-duplicated and managed within the MASCRC data platform. Data were collected on demographics, initial symptoms, diagnostic delay, treatment history, quality of life, psychological distress, and support needs. Descriptive statistics, chi-square tests, and Mann\u2013Whitney U tests were performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 152 valid responses were analyzed from MAS patients across 28 of 34 provincial-level regions, including 94 females (61.84%) and 58 males (38.16%), with a median age of 10.10 years (IQR: 7.80\u201315.00). The most common first symptoms were bone involvement (61.18%), peripheral precocious puberty (36.84%), and caf\u00e9-au-lait pigmentation (37.50%). Initial hyperthyroidism and Cushing syndrome were reported in 3.95% and 1.32% of cases, respectively. Median age at symptom onset was 5.50 years; median age at diagnosis was 6.00 years. Although the majority of patients were diagnosed within 1 year (median delay: 0 months, IQR: 0\u20136), 21.05% experienced a diagnostic delay of \u2265\u20091 year, and 27.63% reported prior misdiagnosis.\n                      <jats:italic>GNAS<\/jats:italic>\n                      mutation testing was performed in 48.68% of patients, with a detection rate of 36.49%. Long-term consistent treatment was reported by 37.00% of respondents, with regular follow-up (62.50%), medication (38.82%), and surgery (36.18%) being the most common strategies. Impact on daily life was substantial: 46.05% of patients reported moderate to severe disruption in education or employment, and family\/economic burden was rated most severe (mean score 3.21\/5). Self-reported psychological distress was common, with 78.29% reporting anxiety-related symptoms and 37.50% reporting depressive symptoms, yet only 15.79% accessed professional support. Over 90% expressed unmet needs for expert medical resources, while 79.61% desired improved insurance reimbursement, and 46.05% wished for peer-support platforms.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>MAS patients in China report substantial clinical and psychosocial burdens, with a subset experiencing prolonged diagnostic journeys and misdiagnoses. These findings highlight a need for earlier recognition, integrated multidisciplinary care, and structured patient support.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-026-04507-y","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T10:32:24Z","timestamp":1784111544000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Diagnostic delay, misdiagnosis, and patient-reported psychosocial burden among Chinese individuals with McCune\u2013Albright syndrome: a national cross-sectional survey"],"prefix":"10.1186","volume":"21","author":[{"given":"Ke","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanlan","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4273-1341","authenticated-orcid":false,"given":"Chunlin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"4507_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1750-1172-3-12","volume":"3","author":"CE Dumitrescu","year":"2008","unstructured":"Dumitrescu CE, Collins MT. McCune-Albright syndrome. Orphanet J Rare Dis. 2008;3:12.","journal-title":"Orphanet J Rare Dis"},{"issue":"Suppl 2","key":"4507_CR2","doi-asserted-by":"publisher","first-page":"P120","DOI":"10.1359\/jbmr.06s223","volume":"21","author":"LS Weinstein","year":"2006","unstructured":"Weinstein LS. G(s)alpha mutations in fibrous dysplasia and McCune-Albright syndrome. J Bone Min Res. 2006;21(Suppl 2):P120\u2013124.","journal-title":"J Bone Min Res"},{"issue":"Suppl 1","key":"4507_CR3","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1186\/1750-1172-7-S1-S4","volume":"7","author":"MT Collins","year":"2012","unstructured":"Collins MT, Singer FR, Eugster E. McCune-Albright syndrome and the extraskeletal manifestations of fibrous dysplasia. Orphanet J Rare Dis. 2012;7(Suppl 1):S4.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"4507_CR4","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13023-024-03036-w","volume":"19","author":"K Song","year":"2024","unstructured":"Song K, Shrestha R, Delaney H, et al. Diagnostic journey for individuals with fibrous dysplasia \/ McCune albright syndrome (FD\/MAS). Orphanet J Rare Dis. 2024;19(1):50. https:\/\/doi.org\/10.1186\/s13023-024-03036-w. Published 2024 Feb 7.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"4507_CR5","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13023-016-0496-x","volume":"11","author":"EK Cho","year":"2016","unstructured":"CEK, KJ, YA, et al. Clinical and endocrine characteristics and genetic analysis of Korean children with McCune-Albright syndrome: a retrospective cohort study. Orphanet J Rare Dis. 2016;11(1):113. https:\/\/doi.org\/10.1186\/s13023-016-0496-x. Published 2016 Aug 9.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"4507_CR6","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s41687-021-00304-2","volume":"5","author":"A Konradi","year":"2021","unstructured":"Konradi A. Assessing quality of life in pediatric fibrous dysplasia and McCune Albright syndrome: PEDS-QL and HADS data from the Fibrous Dysplasia Foundation Patient Registry[J]. J Patient-Reported Outcomes. 2021;5(1):34.","journal-title":"J Patient-Reported Outcomes"},{"key":"4507_CR7","doi-asserted-by":"publisher","first-page":"bcr2013201196","DOI":"10.1136\/bcr-2013-201196","volume":"2013","author":"M Al-Ashqar","year":"2013","unstructured":"Al-Ashqar M, Gowlett S, Baxter I. Diagnostic difficulties delaying treatment in a patient with fibrous dysplasia of the right femur. BMJ Case Rep. 2013;2013:bcr2013201196.","journal-title":"BMJ Case Rep"},{"key":"4507_CR8","doi-asserted-by":"crossref","unstructured":"Benito-Lozano J, Arias-Merino G, G\u00f3mez-Mart\u00ednez M, Ancochea-D\u00edaz A, Aparicio-Garc\u00eda A, de la Posada M et al. Diagnostic process in Rare diseases: determinants Associated with Diagnostic Delay. Int J Environ Res Public Health 2022;19.","DOI":"10.3390\/ijerph19116456"},{"key":"4507_CR9","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1002\/jbmr.4766","volume":"38","author":"KL Roszko","year":"2023","unstructured":"Roszko KL, Guthrie L, Li X, Collins MT, de Castro LF, Boyce AM. Identification of GNAS variants in circulating cell-free DNA from patients with fibrous Dysplasia\/McCune Albright Syndrome. J Bone Min Res. 2023;38:443\u201350.","journal-title":"J Bone Min Res"},{"key":"4507_CR10","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1530\/eje.1.02301","volume":"155","author":"N Kalfa","year":"2006","unstructured":"Kalfa N, Philibert P, Audran F, Ecochard A, Hannon T, Lumbroso S, Sultan C. Searching for somatic mutations in McCune-Albright syndrome: a comparative study of the peptidic nucleic acid versus the nested PCR method based on 148 DNA samples. Eur J Endocrinol. 2006;155:839\u201343.","journal-title":"Eur J Endocrinol"},{"key":"4507_CR11","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.jmoldx.2011.07.003","volume":"13","author":"ST Lee","year":"2011","unstructured":"Lee ST, Kim JY, Kown MJ, Kim SW, Chung JH, Ahn MJ, Oh YL, Kim JW, Ki CS. Mutant enrichment with 3\u2032-modified oligonucleotides a practical PCR method for detecting trace mutant DNAs. J Mol Diagn. 2011;13:657\u201368.","journal-title":"J Mol Diagn"},{"issue":"5","key":"4507_CR12","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s00223-019-00550-z","volume":"104","author":"I Hartley","year":"2019","unstructured":"Hartley I, Zhadina M, Collins MT, Boyce AM. Fibrous Dysplasia of Bone and McCune-Albright Syndrome: A Bench to Bedside Review. Calcif Tissue Int. 2019;104(5):517\u201329. https:\/\/doi.org\/10.1007\/s00223-019-00550-z.","journal-title":"Calcif Tissue Int"},{"key":"4507_CR13","doi-asserted-by":"publisher","first-page":"204201882513473","DOI":"10.1177\/20420188251347350","volume":"16","author":"KL Wentworth","year":"2025","unstructured":"Wentworth KL, Park J, Yu X, Hsiao EC. Update on the medical management of fibrous dysplasia of the bone. Ther Adv Endocrinol Metab. 2025;16:20420188251347350. https:\/\/doi.org\/10.1177\/20420188251347350. Published 2025 Jun 18.","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"1","key":"4507_CR14","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13023-017-0629-x","volume":"12","author":"BCJ Majoor","year":"2017","unstructured":"Majoor BCJ, Andela CD, Bruggemann J, et al. Determinants of impaired quality of life in patients with fibrous dysplasia[J]. Orphanet J Rare Dis. 2017;12(1):80.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"4507_CR15","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s13023-022-02337-2","volume":"17","author":"G Zanello","year":"2022","unstructured":"Zanello G, Chan CH, Pearce DA, et al. Recommendations from the IRDiRC Working Group on methodologies to assess the impact of diagnoses and therapies on rare disease patients[J]. Orphanet J Rare Dis. 2022;17(1):181.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"4507_CR16","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s13023-017-0676-3","volume":"12","author":"V H\u00e9on-Klin","year":"2017","unstructured":"H\u00e9on-Klin V. European Reference networks for rare diseases: what is the conceptual framework?[J]. Orphanet J Rare Dis. 2017;12(1):137.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"4507_CR17","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s12687-021-00521-8","volume":"12","author":"B Tumiene","year":"2021","unstructured":"Tumiene B, Graessner H, Mathijssen IMJ, et al. European Reference Networks: challenges and opportunities[J]. J Community Genet. 2021;12(2):217\u201329.","journal-title":"J Community Genet"},{"issue":"5","key":"4507_CR18","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1159\/000435852","volume":"18","author":"C Morciano","year":"2015","unstructured":"Morciano C, Laricchiuta P, Taruscio D, et al. European Reference Networks and guideline development and use: challenges and opportunities[J]. Public Health Genomics. 2015;18(5):318\u201320.","journal-title":"Public Health Genomics"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-026-04507-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04507-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04507-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:05:23Z","timestamp":1791821123000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-026-04507-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4507"],"URL":"https:\/\/doi.org\/10.1186\/s13023-026-04507-y","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"19 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Institutional Review Board of The First Affiliated Hospital, Zhejiang University School of Medicine (Approval No. 2023\u2009\u2212\u20090629). Electronic informed consent was obtained from all participants; for respondents under 18 years of age, consent was obtained from a parent or legal guardian.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"<b>Declarations<\/b>"}},{"value":"Not applicable. The survey collected no identifiable personal information; no individual person\u2019s data (images, videos, or clinical details) are presented.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"<b>Declarations<\/b>"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"<b>Declarations<\/b>"}}],"article-number":"355"}}